Travast Plus - Travoprost + Timolol Maleate | VetSafeCare.Com

Brand

Travast Plus

Travoprost + Timolol Maleate — Incepta Pharmaceuticals Ltd.
(0.004% + 0.5%) / ophthalmic solution

Alternatives

3

Routes

OPH

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Ophthalmic Solution · (0.004% + 0.5%) / ophthalmic solution

3 ml

৳500

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Instill one drop in the conjunctival sac of the affected eye(s) once daily at about the same time each day, preferably in the evening.

Clinical notes

Applications:

N/A

Indication Notes:
This Sterile Ophthalmic Solution is indicated for the treatment of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to single therapy with prostaglandin analogue or topical beta blocker.
Avoid In:

N/A

Contraindication Notes:
Contraindicated in patients who are hypersensitive to Travoprost, Timolol or any of the components of this preparation.
Travoprost and Timolol reduce intraocular pressure (IOP) by complementary mechanisms of action. Travoprost is a prostaglandin analogue which reduces IOP by increasing trabecular outflow & uveoscleral outflow. Timolol is a non-selective beta adrenergic receptor blocker that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane stabilizing) activity. It lowers IOP by decreasing the formation of aqueous humor in the ciliary epithelium.
No serious adverse reactions are reported. Most frequently reported side effects are ocular hyperemia.
Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. It should not be used during pregnancy.Use in lactation: Caution should be exercised when Travoprost + Timolol Maleate is administered to a nursing mother.
For ophthalmic use only. Patients should remove their contact lenses prior to instilling this preparation and should not insert their lenses until 15 minutes after instillation of the preparation.
Use in children: Safety and effectiveness in pediatric patients have not been established.Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.